Skip to main content
Erschienen in: Calcified Tissue International 3/2020

15.11.2019 | Original Research

Evaluation of a Panel of MicroRNAs that Predicts Fragility Fracture Risk: A Pilot Study

verfasst von: Aurélie Ladang, Charlotte Beaudart, Médéa Locquet, Jean-Yves Reginster, Olivier Bruyère, Etienne Cavalier

Erschienen in: Calcified Tissue International | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

The assessment of fragility fracture risk based on bone densitometry and FRAX°, although commonly used, has shown some limitations. MicroRNAs (miRNAs) are promising biomarkers known to regulate post-transcriptional gene expression. Many studies have already shown that microRNAs are involved in bone homeostasis by modulating osteoblast and osteoclast gene expression. In this pilot study, we investigated the ability of an miRNA panel (namely, the OsteomiR° score) to predict fragility fracture risk in older people. miRNAs were extracted from the sera of 17 persons who developed a fracture within 3 years of collecting the serum and 16 persons who did not experience fractures in the same period. Nineteen miRNAs known to be involved in bone homeostasis were assessed, and 10 miRNAs were employed to calculate the OsteomiR° score. We found a trend towards higher OsteomiR° scores in individuals who experienced fractures compared to control subjects. The most suitable cut-off that maximized sensitivity and specificity was determined by ROC curve analysis, and a positive predictive value of 68% and a sensitivity of 76% were obtained. The OsteomiR° score was higher in osteopenic and osteoporotic subjects compared to subjects with a normal T score. Additionally, the OsteomiR° score predicted more fracture events than the recommended “need-to-treat” thresholds based on FRAX° 10-year probability. miRNAs reflect impairments in bone homeostasis several years before the occurrence of a fracture. The OsteomiR° score seems to be a promising miRNA panel for fragility fracture risk prediction and might have added value compared to FRAX°. Given the limited cohort size, further studies should be dedicated to validating the OsteomiR° score.
Literatur
1.
Zurück zum Zitat Reginster JY, Burlet N (2006) Osteoporosis: a still increasing prevalence. Bone 38(2):4–9CrossRef Reginster JY, Burlet N (2006) Osteoporosis: a still increasing prevalence. Bone 38(2):4–9CrossRef
2.
Zurück zum Zitat Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22(3):465–475PubMedCrossRef Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22(3):465–475PubMedCrossRef
3.
Zurück zum Zitat Randell AG, Nguyen TV, Bhalerao N, Silverman SL, Sambrook PN, Eisman JA (2000) Deterioration in quality of life following hip fracture: a prospective study. Osteoporos Int 11(5):460–466PubMedCrossRef Randell AG, Nguyen TV, Bhalerao N, Silverman SL, Sambrook PN, Eisman JA (2000) Deterioration in quality of life following hip fracture: a prospective study. Osteoporos Int 11(5):460–466PubMedCrossRef
4.
Zurück zum Zitat Melton LJ, Johnell O, Lau E, Mautalen CA, Seeman E (2004) Osteoporosis and the global competition for health care resources. J Bone Miner Res 19(7):1055–1058PubMedCrossRef Melton LJ, Johnell O, Lau E, Mautalen CA, Seeman E (2004) Osteoporosis and the global competition for health care resources. J Bone Miner Res 19(7):1055–1058PubMedCrossRef
5.
Zurück zum Zitat Reid IR (2015) Efficacy, effectiveness and side effects of medications used to prevent fractures. J Intern Med 277(6):690–706PubMedCrossRef Reid IR (2015) Efficacy, effectiveness and side effects of medications used to prevent fractures. J Intern Med 277(6):690–706PubMedCrossRef
6.
Zurück zum Zitat Camacho PM et al (2016) American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis-executive summary. Endocr Pract 22(4):1–42PubMedCrossRef Camacho PM et al (2016) American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis-executive summary. Endocr Pract 22(4):1–42PubMedCrossRef
7.
Zurück zum Zitat Johnell O et al (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20(7):1185–1194PubMedCrossRef Johnell O et al (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20(7):1185–1194PubMedCrossRef
8.
Zurück zum Zitat Siris ES et al (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. J Am Med Assoc 286(22):2815–2822CrossRef Siris ES et al (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. J Am Med Assoc 286(22):2815–2822CrossRef
9.
Zurück zum Zitat Kanis JA et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18(8):1033–1046CrossRefPubMed Kanis JA et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18(8):1033–1046CrossRefPubMed
11.
Zurück zum Zitat Sambrook PN et al (2007) Influence of fall related factors and bone strength on fracture risk in the frail elderly. Osteoporos Int 18(5):603–610PubMedCrossRef Sambrook PN et al (2007) Influence of fall related factors and bone strength on fracture risk in the frail elderly. Osteoporos Int 18(5):603–610PubMedCrossRef
12.
Zurück zum Zitat Giangregorio LM et al (2012) FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res 27(2):301–308PubMedCrossRef Giangregorio LM et al (2012) FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res 27(2):301–308PubMedCrossRef
13.
14.
Zurück zum Zitat Walter E, Dellago H, Grillari J, Dimai HP, Hackl M (2018) Cost-utility analysis of fracture risk assessment using microRNAs compared with standard tools and no monitoring in the Austrian female population. Bone 108:44–54PubMedCrossRef Walter E, Dellago H, Grillari J, Dimai HP, Hackl M (2018) Cost-utility analysis of fracture risk assessment using microRNAs compared with standard tools and no monitoring in the Austrian female population. Bone 108:44–54PubMedCrossRef
15.
Zurück zum Zitat Hackl M, Heilmeier U, Weilner S, Grillari J (2016) Circulating microRNAs as novel biomarkers for bone diseases—complex signatures for multifactorial diseases? Mol Cell Endocrinol 432:83–95PubMedCrossRef Hackl M, Heilmeier U, Weilner S, Grillari J (2016) Circulating microRNAs as novel biomarkers for bone diseases—complex signatures for multifactorial diseases? Mol Cell Endocrinol 432:83–95PubMedCrossRef
16.
Zurück zum Zitat Foessl I, Kotzbeck P, Obermayer-Pietsch B (2019) miRNAs as novel biomarkers for bone related diseases. J Lab Precis Med 4(2–2):2–2CrossRef Foessl I, Kotzbeck P, Obermayer-Pietsch B (2019) miRNAs as novel biomarkers for bone related diseases. J Lab Precis Med 4(2–2):2–2CrossRef
17.
Zurück zum Zitat Tie Y, Liu B, Fu H, Zheng X (2009) Circulating miRNA and cancer diagnosis. Sci China Ser C Life Sci 52(12):1117–1122CrossRef Tie Y, Liu B, Fu H, Zheng X (2009) Circulating miRNA and cancer diagnosis. Sci China Ser C Life Sci 52(12):1117–1122CrossRef
18.
Zurück zum Zitat Meder B et al (2011) MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Res Cardiol 106(1):13–23PubMedCrossRef Meder B et al (2011) MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Res Cardiol 106(1):13–23PubMedCrossRef
19.
Zurück zum Zitat McClelland AD, Kantharidis P (2013) microRNA in the development of diabetic complications. Clin Sci 126(2):95–110CrossRef McClelland AD, Kantharidis P (2013) microRNA in the development of diabetic complications. Clin Sci 126(2):95–110CrossRef
20.
Zurück zum Zitat He P et al (2016) miR-141 modulates osteoblastic cell proliferation by regulating the target gene of IncRNA H19 and IncRNA H19-derived miR-675. Am J Transl Res 8(4):1780–1788PubMedPubMedCentral He P et al (2016) miR-141 modulates osteoblastic cell proliferation by regulating the target gene of IncRNA H19 and IncRNA H19-derived miR-675. Am J Transl Res 8(4):1780–1788PubMedPubMedCentral
23.
Zurück zum Zitat Cao F, Zhan J, Chen X, Zhang K, Lai R, Feng Z (2017) miR-214 promotes periodontal ligament stem cell osteoblastic differentiation by modulating Wnt/β-catenin signaling. Mol Med Rep 16(6):9301–9308PubMedPubMedCentralCrossRef Cao F, Zhan J, Chen X, Zhang K, Lai R, Feng Z (2017) miR-214 promotes periodontal ligament stem cell osteoblastic differentiation by modulating Wnt/β-catenin signaling. Mol Med Rep 16(6):9301–9308PubMedPubMedCentralCrossRef
25.
26.
Zurück zum Zitat Peng H, Lu SL, Bai Y, Fang X, Huang H, Zhuang XQ (2018) MiR-133a inhibits fracture healing via targeting RUNX2/BMP2. Eur Rev Med Pharmacol Sci 22(9):2519–2526PubMed Peng H, Lu SL, Bai Y, Fang X, Huang H, Zhuang XQ (2018) MiR-133a inhibits fracture healing via targeting RUNX2/BMP2. Eur Rev Med Pharmacol Sci 22(9):2519–2526PubMed
27.
Zurück zum Zitat Deng Y et al (2013) Effects of a miR-31, Runx2, and Satb2 regulatory loop on the osteogenic differentiation of bone mesenchymal stem cells. Stem Cells Dev 22(16):2278–2286PubMedCrossRef Deng Y et al (2013) Effects of a miR-31, Runx2, and Satb2 regulatory loop on the osteogenic differentiation of bone mesenchymal stem cells. Stem Cells Dev 22(16):2278–2286PubMedCrossRef
28.
Zurück zum Zitat Zhang L et al (2017) Overexpression of MiR-335-5p promotes bone formation and regeneration in mice. J Bone Miner Res 32(12):2466–2475PubMedCrossRef Zhang L et al (2017) Overexpression of MiR-335-5p promotes bone formation and regeneration in mice. J Bone Miner Res 32(12):2466–2475PubMedCrossRef
29.
Zurück zum Zitat Huang J, Song G, Yin Z, Fu Z, Ye Z (2017) MiR-29a and messenger RNA expression of bone turnover markers in canonical Wnt pathway in patients with ankylosing spondylitis. Clin Lab 63(5–6):955–960PubMed Huang J, Song G, Yin Z, Fu Z, Ye Z (2017) MiR-29a and messenger RNA expression of bone turnover markers in canonical Wnt pathway in patients with ankylosing spondylitis. Clin Lab 63(5–6):955–960PubMed
30.
Zurück zum Zitat Mäkitie RE, Hackl M, Niinimäki R, Kakko S, Grillari J, Mäkitie O (2018) Altered MicroRNA profile in osteoporosis caused by impaired WNT signaling. J. Clin. Endocrinol. Metab. 103(5):1985–1996PubMedCrossRef Mäkitie RE, Hackl M, Niinimäki R, Kakko S, Grillari J, Mäkitie O (2018) Altered MicroRNA profile in osteoporosis caused by impaired WNT signaling. J. Clin. Endocrinol. Metab. 103(5):1985–1996PubMedCrossRef
32.
Zurück zum Zitat Seeliger C et al (2014) Five freely circulating miRNAs and bone tissue miRNAs are associated with osteoporotic fractures. J Bone Miner Res 29(8):1718–1728PubMedCrossRef Seeliger C et al (2014) Five freely circulating miRNAs and bone tissue miRNAs are associated with osteoporotic fractures. J Bone Miner Res 29(8):1718–1728PubMedCrossRef
33.
Zurück zum Zitat Kocijan R et al (2016) Circulating microRNA signatures in patients with idiopathic and postmenopausal osteoporosis and fragility fractures. J Clin Endocrinol Metab 101(11):4125–4134PubMedCrossRef Kocijan R et al (2016) Circulating microRNA signatures in patients with idiopathic and postmenopausal osteoporosis and fragility fractures. J Clin Endocrinol Metab 101(11):4125–4134PubMedCrossRef
34.
Zurück zum Zitat Feichtinger X et al (2018) Bone-related circulating MicroRNAs miR-29b-3p, miR-550a-3p, and miR-324-3p and their Association to Bone Microstructure and Histomorphometry. Sci Rep 8(1):4867PubMedPubMedCentralCrossRef Feichtinger X et al (2018) Bone-related circulating MicroRNAs miR-29b-3p, miR-550a-3p, and miR-324-3p and their Association to Bone Microstructure and Histomorphometry. Sci Rep 8(1):4867PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Heilmeier U et al (2016) Serum miRNA signatures are indicative of skeletal fractures in postmenopausal women with and without type 2 diabetes and influence osteogenic and adipogenic differentiation of adipose tissue-derived mesenchymal stem cells in vitro. J Bone Miner Res 31(12):2173–2192PubMedCrossRef Heilmeier U et al (2016) Serum miRNA signatures are indicative of skeletal fractures in postmenopausal women with and without type 2 diabetes and influence osteogenic and adipogenic differentiation of adipose tissue-derived mesenchymal stem cells in vitro. J Bone Miner Res 31(12):2173–2192PubMedCrossRef
36.
Zurück zum Zitat Beaudart C et al (2015) Quality of life and physical components linked to sarcopenia: the SarcoPhAge study. Exp Gerontol 69:103–110PubMedCrossRef Beaudart C et al (2015) Quality of life and physical components linked to sarcopenia: the SarcoPhAge study. Exp Gerontol 69:103–110PubMedCrossRef
37.
Zurück zum Zitat Norlund L et al (1997) Reference intervals for the glomerular filtration rate and cell-proliferation markers: serum cystatin C and serum β2-microglobulin/cystatin C-ratio. Scand J Clin Lab Investig 57(6):463–470CrossRef Norlund L et al (1997) Reference intervals for the glomerular filtration rate and cell-proliferation markers: serum cystatin C and serum β2-microglobulin/cystatin C-ratio. Scand J Clin Lab Investig 57(6):463–470CrossRef
38.
Zurück zum Zitat Johansson H et al (2011) A FRAX® model for the assessment of fracture probability in Belgium. Osteoporos Int 22(2):453–461PubMedCrossRef Johansson H et al (2011) A FRAX® model for the assessment of fracture probability in Belgium. Osteoporos Int 22(2):453–461PubMedCrossRef
39.
Zurück zum Zitat Briot K et al (2012) Actualisation 2012 des recommandations françaises du traitement médicamenteux de l’ostéoporose post-ménopausique. Revue du rhumatisme. 79(3):264–274CrossRef Briot K et al (2012) Actualisation 2012 des recommandations françaises du traitement médicamenteux de l’ostéoporose post-ménopausique. Revue du rhumatisme. 79(3):264–274CrossRef
40.
Zurück zum Zitat Chen Y, Alman BA (2009) Wnt pathway, an essential role in bone regeneration. J Cell Biochem 106(3):353–362PubMedCrossRef Chen Y, Alman BA (2009) Wnt pathway, an essential role in bone regeneration. J Cell Biochem 106(3):353–362PubMedCrossRef
41.
Zurück zum Zitat Kanis JA, Oden A, Johansson H, McCloskey E (2012) Pitfalls in the external validation of FRAX. Osteoporos Int 23(2):423–431PubMedCrossRef Kanis JA, Oden A, Johansson H, McCloskey E (2012) Pitfalls in the external validation of FRAX. Osteoporos Int 23(2):423–431PubMedCrossRef
42.
Zurück zum Zitat Aubry-Rozier B, Stoll D, Krieg MA, Lamy O, Hans D (2013) What was your fracture risk evaluated by FRAX® the day before your osteoporotic fracture? Clin Rheumatol 32(2):219–223PubMedCrossRef Aubry-Rozier B, Stoll D, Krieg MA, Lamy O, Hans D (2013) What was your fracture risk evaluated by FRAX® the day before your osteoporotic fracture? Clin Rheumatol 32(2):219–223PubMedCrossRef
43.
Zurück zum Zitat Chen XF, Li XL, Zhang H, Liu GJ (2014) Were you identified to be at high fracture risk by FRAX® before your osteoporotic fracture occurred? Clin Rheumatol 33(5):693–698PubMedCrossRef Chen XF, Li XL, Zhang H, Liu GJ (2014) Were you identified to be at high fracture risk by FRAX® before your osteoporotic fracture occurred? Clin Rheumatol 33(5):693–698PubMedCrossRef
44.
45.
Zurück zum Zitat Poynard T et al (2011) Applicability and precautions of use of liver injury biomarker FibroTest A reappraisal at 7 years of age. BMC Gastroenterol 11(39):39PubMedPubMedCentralCrossRef Poynard T et al (2011) Applicability and precautions of use of liver injury biomarker FibroTest A reappraisal at 7 years of age. BMC Gastroenterol 11(39):39PubMedPubMedCentralCrossRef
Metadaten
Titel
Evaluation of a Panel of MicroRNAs that Predicts Fragility Fracture Risk: A Pilot Study
verfasst von
Aurélie Ladang
Charlotte Beaudart
Médéa Locquet
Jean-Yves Reginster
Olivier Bruyère
Etienne Cavalier
Publikationsdatum
15.11.2019
Verlag
Springer US
Erschienen in
Calcified Tissue International / Ausgabe 3/2020
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-019-00628-8

Weitere Artikel der Ausgabe 3/2020

Calcified Tissue International 3/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.